图片来源:界面图库界面新闻记者 |李科文界面新闻编辑 |许悦国产创新药物联合疗法击败全球“药王”帕博利珠单抗。6月4日,港股上市公司中国生物制药公告,其贝莫苏拜单抗注射液联合盐酸安罗替尼胶囊(下简称:得福组合),一线治疗PD-L1阳性晚期非小细胞肺癌的中位无进展生存期(PFS)达到11个月,头对头击败全球“药王”帕博利珠单抗,较帕博利珠单抗治疗提升3.9个月。同时,得福组合在一线治疗局部晚期或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.